Cargando…

Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients

COVID-19 is characterized by a dysregulation of inflammatory cytokines ultimately resulting a cytokine storm that can result in significant morbidity and mortality. We developed an in-vitro assay using activated peripheral blood mononuclear cells (PBMCs) stimulated with lipopolysaccharide (LPS) or C...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathi, Kavita, Rosenberg-Hasson, Yael, Maecker, Holden, Carlo, Dennis J., Moss, Ronald B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378988/
https://www.ncbi.nlm.nih.gov/pubmed/34425240
http://dx.doi.org/10.1016/j.clim.2021.108828
_version_ 1783740916225277952
author Mathi, Kavita
Rosenberg-Hasson, Yael
Maecker, Holden
Carlo, Dennis J.
Moss, Ronald B.
author_facet Mathi, Kavita
Rosenberg-Hasson, Yael
Maecker, Holden
Carlo, Dennis J.
Moss, Ronald B.
author_sort Mathi, Kavita
collection PubMed
description COVID-19 is characterized by a dysregulation of inflammatory cytokines ultimately resulting a cytokine storm that can result in significant morbidity and mortality. We developed an in-vitro assay using activated peripheral blood mononuclear cells (PBMCs) stimulated with lipopolysaccharide (LPS) or CD3 + CD28 to examine secretion of cytokines from antigen presenting cells (APCs) and T cells, respectively, in donor patients with a history of COVID-19 (convalescent) and uninfected negative controls. We hypothesized that a novel antioxidant called Tempol may decrease cytokines from activated peripheral blood cells from both COVID-19 patients and normal donors. Preincubation of immune cells with Tempol resulted in a significant (P < 0.05) decrease in multiple T cell and APC-derived cytokines from both cells of COVID-19 (n = 7) and uninfected donors (n = 7). These preliminary results suggest that Tempol has strong in-vitro anti-cytokine activity and supports additional studies examining the use of Tempol for the treatment of COVID-19.
format Online
Article
Text
id pubmed-8378988
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-83789882021-08-23 Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients Mathi, Kavita Rosenberg-Hasson, Yael Maecker, Holden Carlo, Dennis J. Moss, Ronald B. Clin Immunol Article COVID-19 is characterized by a dysregulation of inflammatory cytokines ultimately resulting a cytokine storm that can result in significant morbidity and mortality. We developed an in-vitro assay using activated peripheral blood mononuclear cells (PBMCs) stimulated with lipopolysaccharide (LPS) or CD3 + CD28 to examine secretion of cytokines from antigen presenting cells (APCs) and T cells, respectively, in donor patients with a history of COVID-19 (convalescent) and uninfected negative controls. We hypothesized that a novel antioxidant called Tempol may decrease cytokines from activated peripheral blood cells from both COVID-19 patients and normal donors. Preincubation of immune cells with Tempol resulted in a significant (P < 0.05) decrease in multiple T cell and APC-derived cytokines from both cells of COVID-19 (n = 7) and uninfected donors (n = 7). These preliminary results suggest that Tempol has strong in-vitro anti-cytokine activity and supports additional studies examining the use of Tempol for the treatment of COVID-19. The Author(s). Published by Elsevier Inc. 2021-10 2021-08-21 /pmc/articles/PMC8378988/ /pubmed/34425240 http://dx.doi.org/10.1016/j.clim.2021.108828 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Mathi, Kavita
Rosenberg-Hasson, Yael
Maecker, Holden
Carlo, Dennis J.
Moss, Ronald B.
Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients
title Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients
title_full Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients
title_fullStr Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients
title_full_unstemmed Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients
title_short Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients
title_sort brief report: tempol, a novel antioxidant, inhibits both activated t cell and antigen presenting cell derived cytokines in-vitro from covid-19 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378988/
https://www.ncbi.nlm.nih.gov/pubmed/34425240
http://dx.doi.org/10.1016/j.clim.2021.108828
work_keys_str_mv AT mathikavita briefreporttempolanovelantioxidantinhibitsbothactivatedtcellandantigenpresentingcellderivedcytokinesinvitrofromcovid19patients
AT rosenberghassonyael briefreporttempolanovelantioxidantinhibitsbothactivatedtcellandantigenpresentingcellderivedcytokinesinvitrofromcovid19patients
AT maeckerholden briefreporttempolanovelantioxidantinhibitsbothactivatedtcellandantigenpresentingcellderivedcytokinesinvitrofromcovid19patients
AT carlodennisj briefreporttempolanovelantioxidantinhibitsbothactivatedtcellandantigenpresentingcellderivedcytokinesinvitrofromcovid19patients
AT mossronaldb briefreporttempolanovelantioxidantinhibitsbothactivatedtcellandantigenpresentingcellderivedcytokinesinvitrofromcovid19patients